Ohio Pediatric Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$27,859	10
2024	Research	$216,790	485
2023	Research	$158,310	91
2022	Research	$24,291	22
2019	Research	$148,503	13

Breakdown

Who paid Research payments · program years 2019–2025

Dermavant Sciences, Inc. $228,250 549 payments
GlaxoSmithKline, LLC. $198,569 58 payments
Shire North American Group Inc $148,503 13 payments
Pfizer Inc. $430 1 payment

Studies the money was for Research payments · program years 2019–2025

An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $121,829 102 payments
A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the $120,594 33 payments
An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $106,421 447 payments
Safety and Tolerability Study of Shp465 in Children Aged 4 to 12 Years Diagnosed With Attention-Deficithyperactivity Disorder Adhd $90,989 5 payments
A Phase II, Observer-Blind, Randomized, Controlled Study to Evaluate T $66,935 17 payments
A Phase 1 Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of D- and L-Amphetamine After Multiple Daily Doses of Shp465 6.25 MG Administered in Children Aged 4 to 5 Years With Attention-Deficithyperactivity Disorder $49,169 3 payments
Efficacy and Safety of Shp465 at 6.25 MG in the Treatment of Attention-Deficithyperactivity Disorder Adhd in Children Aged 6-12 Years $8,346 5 payments
A Phase 3A, Open-Label, Randomized, Controlled Study to Evaluate the I $7,490 3 payments
Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $3,150 4 payments
A Phase 3 Randomized Activecontrolled Observerblinded Study to Assess the Immunogenicity Safety and Tolerability of Bivalent Rlp2086 When Administered As A 2Dose Regimen and A Firstinhuman Study to Describe the Immunogenicity Safety and Tolerability of A Bivalent Rlp2086containing Pentavalent Vaccine Menabcwy in Healthy Subjects10 to 26 Years of Age $430 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.